



Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60390-IA/JPW/GJG/ML		Serial No. 10/718,280						
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Arlindo L. Castelhana et al.								
				Filing Date November 20, 2003		Group 1624						
U.S. PATENT DOCUMENTS												
Examiner Initial		Document Number				Date	Name	Class	Subclass	Filing Date if Appropriate		
	1	5	2	9	6	4	8	4	3/22/94	Coghlan et al.		
	2	5	6	4	6	1	3	0	7/8/97	Shi		
	3	5	8	7	7	1	8	0	3/2/99	Linden et al.		
	4	5	8	8	9	0	2	6	3/30/99	Alanine et al.		
	5	5	9	3	5	9	6	4	8/10/99	Baraldi et al.		
	6	6	1	1	7	8	7	8	9/12/00	Linden		
	7	6	4	6	5	4	5	6	10/15/02	Springer et al.		
	8	6	9	1	6	8	0	4	7/12/05	Castelhana et al.		
	9	7	2	0	2	2	5	2	4/10/07	Wilson et al.		
	10	20	03	01	39	4	2	7	11/1/05	Castelhana et al.		
	11	20	03	02	29	0	6	7	12/11/03	Castelhana et al.		
	12	20	05	01	19	2	7	1	6/2/05	Castelhana et al.		
	13	20	04	00	82	5	9	9	4/29/04	Castelhana et al.		
	14	20	05	00	43	3	3	2	2/24/05	Castelhana et al.		
	15	20	08	00	70	9	3	6	3/20/08	Castelhana et al.		
FOREIGN PATENT DOCUMENTS												
		Document Number				Date	Country	Class	Subclass	Translation		
										Yes	No	
	16	9	7	4	7	6	0	1	12/18/97	PCT		
	17	9	9	6	4	4	0	7	12/16/99	PCT		
	18	9	9	0	8	4	6	0	2/18/99	PCT		
	19	0	0	0	3	7	4	1	1/27/00	PCT		
	20	20	03	05	3	3	6	1	7/3/03	PCT		
	21	20	03	05	3	3	6	6	7/3/03	PCT		
	22	0	7	2	9	7	5	8	9/4/96	EPO		
	23	1	2	4	6	6	2	3	8/9/06	EPO		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)												
	24	Hungarian Patent No. HU P9303515 (corresponds to WO 94/13676)										
	25	Hungarian Patent No. HU P9501230 (corresponds to EP 0682027)										
	26	Hungarian Patent No. HU P9602016 (corresponds to WO 95/19970)										
	27	Hungarian Patent No. HU P9402829 (corresponds to WO 93/20078)										
	28	Hungarian Patent No. HU P9602017 (corresponds to WO 95/19774)										
	29	Abbracchio M., et al., (1997) "Modulation of Apoptosis by Nervous System: a Possible Role for the A3 Receptor", <u>Ann. NY. Acad. Sci.</u> , 825: 11-22										
	30	Aoyama S. et al. (2000) "Rescue of Locomotor Impairment in Dopamine D2 Receptor-Deficient Mice by an Adenosine A2a Receptor Antagonist" <u>J. Neuroscience</u> 20(15) : 5848-5852										
	31	Avila, M.Y. (2001) "A1-A2a and A3-Subtype Adenosine receptors Modulate Intraocular Pressure in the Mouse" <u>J. of Pharmacol.</u> 241-245										
	32	Baraldi, P.G. et al. (1996) "Pyrazolo [4,3-e]-1,2,4 triazolo [1,5-c]pyrimidine Derivatives: Potent and Selective A2a Adenosine Antagonists" <u>J. Med. Chem.</u> 39: 1164-1171										
	33	Baraldi P., et al. (2000) "New potent and selective human adenosine A3 receptor antagonists", <u>Tips</u> , 21: 456-459										
	34	Baraldi P., et al. "Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes", <u>Curr. Pharm. Design</u> 8: 2299-2332, 2002										
EXAMINER						DATE CONSIDERED						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

Applicants: Arlindo Castelhana et al.  
Serial No.: 10/718,280  
Filed: November 20, 2003  
Exhibit A

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>			Atty. Docket No. <b>60390-IA/JPW/GJG/ML</b>		Serial No. <b>10/718,280</b>								
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					Applicants: <b>Arlindo L. Castelhana et al.</b>										
					Filing Date <b>November 20, 2003</b>		Group <b>1624</b>								
<b>U.S. PATENT DOCUMENTS</b>															
Examiner Initial	1	2	3	4	5	6	7	8	Date	Name	Class	Subclass	Filing Date if Appropriate		
	1	5	2	9	6	4	8	4	3/22/94	Coghlan et al.					
	2	5	6	4	6	1	3	0	7/8/97	Shi					
	3	5	8	7	7	1	8	0	3/2/99	Linden et al.					
	4	5	8	8	9	0	2	6	3/30/99	Alanine et al.					
	5	5	9	3	5	9	6	4	8/10/99	Baraldi et al.					
	6	6	1	1	7	8	7	8	9/12/00	Linden					
	7	6	4	6	5	4	5	6	10/15/02	Springer et al.					
	8	6	9	1	6	8	0	4	7/12/05	Castelhana et al.					
	9	7	2	0	2	2	5	2	4/10/07	Wilson et al.					
	10	20	03	01	39	4	2	7	11/1/05	Castelhana et al.					
	11	20	03	02	29	0	6	7	12/11/03	Castelhana et al.					
	12	20	05	01	19	2	7	1	6/2/05	Castelhana et al.					
	13	20	04	00	82	5	9	9	4/29/04	Castelhana et al.					
	14	20	05	00	43	3	3	2	2/24/05	Castelhana et al.					
	15	11	9	0	3	1	4	7	9/20/07	Castelhana et al.					
<b>FOREIGN PATENT DOCUMENTS</b>															
		Document Number							Date	Country	Class	Subclass	Translation		
														Yes	No
	16	9	7	4	7	6	0	1	12/18/97	PCT					
	17	9	9	6	4	4	0	7	12/16/99	PCT					
	18	9	9	0	8	4	6	0	2/18/99	PCT					
	19	0	0	0	3	7	4	1	1/27/00	PCT					
	20	20	03	05	3	3	6	1	7/3/03	PCT					
	21	20	03	05	3	3	6	6	7/3/03	PCT					
	22	0	7	2	9	7	5	8	9/4/96	EPO					
	23	1	2	4	6	6	2	3	8/9/06	EPO					
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>															
	24	Hungarian Patent No. HU P9303515 (corresponds to WO 94/13676)													
	25	Hungarian Patent No. HU P9501230 (corresponds to EP 0682027)													
	26	Hungarian Patent No. HU P9602016 (corresponds to WO 95/19970)													
	27	Hungarian Patent No. HU P9402829 (corresponds to WO 93/20078)													
	28	Hungarian Patent No. HU P9602017 (corresponds to WO 95/19774)													
	29	Abbracchio M., et al., (1997) "Modulation of Apoptosis by Nervous System: a Possible Role for the A3 Receptor", <u>Ann. NY. Acad. Sci.</u> , 825: 11-22													
	30	Aoyama S. et al. (2000) "Rescue of Locomotor Impairment in Dopamine D2 Receptor-Deficient Mice by an Adenosine A2a Receptor Antagonist" <u>J. Neuroscience</u> 20(15) : 5848-5852													
	31	Avila, M.Y. (2001) "A1-A2a and A3-Subtype Adenosine receptors Modulate Intraocular Pressure in the Mouse" <u>J. of Pharmacol.</u> 241-245													
	32	Baraldi, P.G. et al. (1996) "Pyrzolo [4,3-e]-1,2,4 triazolo [1,5-c]pyrimidine Derivatives: Potent and Selective A2a Adenosine Antagonists" <u>J. Med. Chem.</u> 39: 1164-1171													
	33	Baraldi P., et al. (2000) "New potent and selective human adenosine A3 receptor antagonists", <u>Tips</u> , 21: 456-459													
	34	Baraldi P., et al. "Pyrzolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes", <u>Curr. Pharm. Design</u> 8: 2299-2332, 2002													
EXAMINER									DATE CONSIDERED						
<p><b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>															

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>			Atty. Docket No. <b>60390-IA/JPW/GJG/ML</b>		Serial No. <b>10/718,280</b>	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					Applicants: <b>Arlindo Castelhana et al.</b>			
					Filing Date <b>November 20, 2003</b>		Group <b>1624</b>	
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<b>FOREIGN PATENT DOCUMENTS</b>								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
	35	Baraldi, P.G. et al., (1999) "A1 and A3 adenosine receptor agonists: an overview." <i>Expert Opinion on Therapeutic Patents</i> , 9(5):515-527						
	36	Baraldi, P.G. et al., (2004) "Allosteric modulators for the A1 adenosine receptor." <i>Expert Opinion on Therapeutic Patents</i> , 14(1):71-79						
	37	Baraldi, P.G. (2003) "Recent developments in the field of A2A and A3 adenosine receptor antagonists" <i>Eur. J. Med. Chem.</i> 38(4) 367						
	38	Blazynski C., (1990) "Discrete Distributions of Adenosine Receptors in Mammalian Retina", <i>Journal of Neurochemistry</i> , 53: 648-655						
	39	Borman, S. (2001) "A3 Receptors" <i>C&amp;EN</i> , 79(7), 37						
	40	Braas K.M., et al., (1987) "Endogenous adenosine and adenosine receptors localized to ganglion cells of the retina", <i>Proceedings of the National Academy of Science</i> , 84: 3906-3910						
	41	Bradford M. M., (1976) "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding", <i>Anal. Biochem.</i> , 72: 248						
	42	Bremer et al. (2002) "Therapy of Crohn's Disease in Childhood", <i>Expert Opin. Pharmacother.</i> 3(7): 809-825						
	43	Broach, J. R. et al., (1983) "Vectors for high level, inducible expression of cloned genes in yeast", Inouye (ed.), <i>Experimental Manipulation of Gene Expression</i> , Academic Press, New York, 83-117						
	44	Casavola V., et al., (1983) "Adenosine A3 receptor activation increases cytosolic calcium concentration via calcium influx in A6 cells", <i>Drug Development Research</i> , 43 (1): 62						
	45	Cheng, Y. and Prusoff, W. H. (1973) "Relationship Between The Inhibition Constant (Ki) And The Concentration Of Inhibitor Which Causes 50 Per Cent Inhibition (I50) Of An Enzymatic Reaction", <i>Biochem. Pharmacol.</i> , 22: 3099-3109						
	46	Christianson, T. W. et al., (1992) "Multifunctional yeast high-copy-number shuttle vectors", <i>Gene</i> , 110: 119-122						
	47	Christofi, F. L. et al. (2001), "Differential Gene Expression of Adenosine A1, A2a, A2b, and A3 Receptors in the Human Enteric Nervous System", <i>J. Comp. Neurol.</i> 439(1): 46-64						
	48	Coney, A. M. et al. (1998) "Role of Adenosine and its Receptors in the Vasodilation Induced in the Cerebral Cortex of the Rat by Systemic Hypoxia" <i>J. Physiol.</i> 509: 507-518						
	49	Cooper, J. A. (1995) "Adenosine Receptor-induced Cyclic AMP Generation and Inhibition of 5-hydroxytryptamine release in Human Platelets" <i>Br. J. Clin. Pharmacol.</i> 40:43-50						
	50	Corset, V. et al. (2000), "Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor", <i>Nature</i> , 407 (6805): 747-750						
	51	Dubey, R. K. et al. (2001), "A2B Receptors Mediate the Antimitogenic Effects of Adenosine in Cardiac Fibroblasts", <i>Hypertension</i> 37: 716-721						
	52	Duzic, E. et al, (1992) "Factors Determining the Specificity of Signal Transduction by Guanine Nucleotide-binding Protein-coupled Receptors", <i>J. Biol. Chem.</i> , 267: 9844-9851						
	53	Ezeamuzie C., et al. (1999), <i>British Journal of Pharmacology</i> , 127: 188-194						
	54	Faivre, K. et al., (2001) "Suppression of Cellular Invasion by Activated G-Protein Subunits Gao, Gai1, and Gai3 and Sequestration of Gβγ", <i>Mol. Pharmacol.</i> 60: 363-372						
	55	Feoktistov, I. and Biaggioni, I., (1997) "Adenosine A2B Receptors", <i>Pharmacol. Rev.</i> 49(4): 381-402						
EXAMINER			DATE CONSIDERED					
<p><b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60390-1A/JPW/GJG/ML		Serial No. 10/718,280		
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					Applicants: <b>Arlindo Castelhana et al.</b>  Filing Date <b>November 20, 2003</b>				Group <b>1624</b>
<b>U.S. PATENT DOCUMENTS</b>									
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate		
<b>FOREIGN PATENT DOCUMENTS</b>									
		Document Number	Date	Country	Class	Subclass	Translation		
							Yes	No	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>									
	56	Feoktistov, I. et al., (2002) "Differential Expression of Adenosine Receptors in Human Endothelial Cells", <i>Circulation Research</i> 90: 531-538							
	57	Fishman P (2003) "Pharmacology and therapeutic applications of A3 receptor subtype" <i>Curr. Top. Med. Chem.</i> 3(4): 463-9							
	58	Fozard J., et al., (1996) "Mast cell degranulation following adenosine A3 receptor activation in rats", <i>European Journal of Pharmacology</i> , 298: 293-297							
	59	Franco M., et al., (1999) "Adenosine Regulates Renal Nitric Oxide Production in Hypothyroid Rats", <i>Journal of the American Society of Nephrology</i> , 1681-1688							
	60	Gao, Z. et al., "A2B Adenosine and P2Y2 Receptors Stimulate Mitogen-activated Protein Kinase in Human Embryonic Kidney-293 Cells" <i>J. Bio. Chem.</i> (1999) 274(9): 5972-5980							
	61	Ghiardi, G. J. et al. (1999) "The Purine Nucleoside Adenosine in Retinal Ischemia-Reperfusion Injury" <i>Vision Research</i> 39:2519-2535							
	62	GenBank accession # S46950							
	63	GenBank accession numbers S45235 and S56143							
	64	Grant, M.B. et al., (2001) "Proliferation, Migration, and ERK Activation in Human Retinal Endothelial Cells through A2B Adenosine Receptor Stimulation", <i>Invest. Ophthalmol. Vis. Sci.</i> 42(9): 2068-2073							
	65	Guerra L., et al., (1998) "Adenosine A3 receptor activation increases cytosolic calcium influx in A6 cells", <i>Nephrology Dialysis Transplantation</i> , 13 (6): A5							
	66	Guo, Y. et al., (2001) "Targeted deletion of A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning." <i>J Mol Cell Cardiol</i> , 33:825-830							
	67	Haynes, J. Jr. et al., (1999) "5-(N-ethylcarboxamido) adenosine desensitizes the A2b-adenosine receptor in lung circulation", <i>Am. J. Physiol.</i> 276(6): H1877-H1883							
	68	Herndon, J.L. et al., (1992) Herndon, J.L. et al., "Ketanserin Analogs: Structure-Affinity Relationships for 5-HT2 and 5-HT1C Serotonin Receptor Binding", <i>J. Med. Chem.</i> 35(26): 4903-4910							
	69	Hoeschst India Ltd., India "Pharmacologically active pyrimido "[4,5-b]indoles and their salts." Database accession No. 106:84629 HCA XP002121648							
	70	Kanda, T. et al. (1998) "Adenosine A2a Receptors Modify Motor Function in MPTP-treated Common - Marmosets" <i>Neuroreport</i> 9: 2857-2860							
	71	Kanda, T. et al. (2000) "Combined Use of the Adenosine A2a Antagonist KW-6002 with L-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but not Dyskinesia in MPTP-Treated Monkeys" <i>Experimental Neurology</i> 162: 321-327							
	72	Kang, Y. et al., (1990) "Effects of Expression of Mammalian Gα and Hybrid Mammalian-Yeast Gα Proteins on the Yeast Pheromone Response Signal Transduction Pathway", <i>Mol. Cell. Biol.</i> , 10: 2582-2590							
	73	Kiichiro, K. et al. "Synthesis of pyrazinecarboxylic acid derivs. - (II) derivs. of 3-aminopyrazinecarboxylic acid" <i>Chem. Abstracts</i> 56:8713							
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60390-IA/JPW/GJG/ML		Serial No. 10/718,280	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					Applicants: Arlindo Castelhana et al.			
					Filing Date November 20, 2003		Group 1624	
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<b>FOREIGN PATENT DOCUMENTS</b>								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
	74	Kiritsy, J.A. et al., (1978) "Synthesis and Quantitative Structure-Activity Relationships of Some Antibacterial 3-Formylrifamycin SV N-(4-Substituted phenyl) piperazinoacetylhydrazones" J. Med. Chem. 21(12): 1301-1307						
	75	Klumpp, D.A. et al., (1999) "Synthesis of Aryl-Substituted Piperidines by Superacid Activation of Piperidones" J. Org. Chem. 64(18): 6702-6705						
	76	Knutsen, L.J.S. et al. (2001) Curr. Opin. Invest. Drugs 2(5):668-673						
	77	Kopf, S.R. et al. (1999) "Adenosine and Memory Storage: Effect of A1 and A2 Receptor Antagonists" Psychopharmacology 146:214-219						
	78	Li, J.M. et al. (1998) "Adenosine A2a Receptors Increase Arterial Endothelial Cell Nitric Oxide" J. Surg. Res. 80:357-364						
	79	Linden, J. et al., (1998) "The Structure and Function of A1 and A2B Adenosine Receptors" Life Sciences 62(17-18): 1519-1524						
	80	Meade et al., PubMed Abstract (Life Sci. 69(11):1225-40) August 2001						
	81	Mitchell, C.H. et al., "Adenosine A3 Receptor Activation Reduces Cell Volume and Activates Cl <sup>-</sup> Current in Human Ciliary Epithelial Cells", FASEB J, A134 (Abstract only)						
	82	Michell, C.H. (1999) "A3 adenosine receptors regulate Cl <sup>-</sup> channels of nonpigmented ciliary epithelial cells" Am. J. Physiol. 276: C659-C666						
	83	Mirabet, M. et al., (1999) "Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation" J. Cell. Sci. 112(4): 491-502						
	84	Montesinos, M.C. et al. (2002) "Adenosine Promotes Wounds Healings and Mediates Angiogenesis in Response to Tissue Injury Via Occupancy of A2a Receptors" American Journal of Pathology 160(6):2009-2018						
	85	Müller, C.E. et al., "Imidazo [2,1-i] purin-5-ones and Related Tricyclic Water-Soluble Purine Derivatives: Potent A2A- and A3-Adenosine Receptor Antagonists", (2002) J. Med. Chem. 45(16): 3440-3450						
	86	Müller, C.E. (2001) "A3 Adenosine Receptor Antagonists" Mini Reviews in Med. Chem. 1(4): 339						
	87	Nagarathnam, D. et al., (1998) "Design and Synthesis of Novel $\alpha$ 1a Adrenoceptor-Selective Dihydropyridine Antagonists for the Treatment of Benign Prostatic Hyperplasia", J. Med. Chem. 41(26): 5320-5333						
	88	Nishiyama, A. et al. (2001) "Interactions of Adenosine A1 and A2 a Receptors on Renal Microvascular Reactivity" Am. J. Physiol. Renal Physiol. 280:F406-F414						
EXAMINER					DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>			Atty. Docket No. <b>60390-IA/JPW/GJG/ML</b>		Serial No. <b>10/718,280</b>	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					<b>Applicants: Arlindo Castelhana et al.</b>			
					Filing Date <b>November 20, 2003</b>		Group <b>1624</b>	
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<b>FOREIGN PATENT DOCUMENTS</b>								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
	<b>89</b>	Ohana G., et al., (2001) "Differential Effect of Adenosine on Tumor and Normal Cell Growth: Focus on the A3 Adenosine Receptor", <u>Journal of Cellular Physiology</u> , 186: 19-23						
	<b>90</b>	Phillips, J.W. (1995) "The Effects of Selective A1 and A2a Adenosine Receptor Antagonists on Cerebral Ischemic Injury in the Gerbil"						
	<b>91</b>	Polosa (2002) "Adenosine-receptor subtypes: their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease", <u>Eur. Respir. Journal</u> 20,488-496						
	<b>92</b>	Priego, E.-M. et al., "Pyrido [2,1-f]purine-2,4-dione Derivatives as a Novel Class of Highly Potent Human A3 Adenosine Receptor Antagonists", (2002) <u>J. Med. Chem.</u> , 45(16): 3337-3344						
	<b>93</b>	Ralevic, V. And Burnstock, G., (1998) "Receptors for Purines and Pyrimidines", <u>Pharmacol. Rev.</u> 50(3): 413-492						
	<b>94</b>	Regnauld, K. et al., (2002) "G-protein $\alpha$ o subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells", <u>Oncogene</u> 21(25): 4020-4031						
	<b>95</b>	Regulation of Downstream Effectors By GPCRs, (1999) <u>FASEB J.</u> , Abstracts 147.1-147.6						
	<b>96</b>	Reshkin J., et al., (2000) "Activation of A3 Adenosine Receptor Induces Calcium Entry and Chloride Secretion in A6 Cells", <u>J. Membrane Biol.</u> , 178: 103-113						
	<b>97</b>	Robinson, "Medical Therapy of Inflammatory Bowel Disease for the 21st Century", <u>Eur J Surg. Suppl</u> 582:90-98, 1998						
	<b>98</b>	Sawynok J., et al., (1997) "Adenosine A3 receptor activation produces nociceptive behaviour and edema by release of histamine and 5-hydroxytryptamine", <u>European Journal of Pharmacology</u> , 333: 1-7						
	<b>99</b>	Shiozaki, S. et al. (1999) "Actions of Adenosine A2a Receptor Antagonist KW-6002 on Drug-induced Catalepsy and hypokinesia Caused by Reserpine of MPTP" <u>Psychopharmacology</u> 147:90-95						
	<b>100</b>	Simone, <u>Oncology: Introduction Cecil Textbook of Medicine</u> , 20th Edition, Vol. 1, pp. 1004-1010, 1996						
	<b>101</b>	Singh et al., "Immune therapy in inflammatory bowel disease and models of colitis", <u>British Journal of Surgery</u> , 88: 1558-1569, 2001						
	<b>102</b>	Strohmeier, G. R. et al., (1995) "The A2b Adenosine Receptor Mediates cAMP Responses to Adenosine Receptor Agonists in Human Intestinal Epithelia", <u>J. Bio. Chem.</u> , 270: 2387-2394						
	<b>103</b>	Svenningsson, P. et al. (1999) "Distribution, Biochemistry and Function of Striatal Adenosine A2a Receptors" <u>Prog. Neurobiol.</u> 59(4):355-396						
	<b>104</b>	Tanaka, H. et al.' "Preparation and formulation of fused pyrimidine compounds as CRF receptor antagonists." Database accession no. 129:109098 HCA XP002121647						
	<b>105</b>	Taomoto, M. ety al. (2000) "Localization of Adenosine A2 Receptor in Retinal Development and Oxygen-Induced Retinopathy" <u>Investigative Ophthalmology &amp; Visual Science</u> 41(1):230-243						
	<b>106</b>	Van Niel, M.B. et al., "Fluorination of 3-(3-(Piperidin-1-yl)propyl)indoles and 3-(3-(Piperazin-1-yl)propyl)indoles Gives Selective Human 5-Htd Receptor Ligands with Improved Pharmacokinetic Profiles" <u>J. Med. Chem.</u> (1999) 42(12): 2087-2104						
	<b>107</b>	Varani, K. et al. (1998) "[ <sup>3</sup> H]-SCH 58261 Labelling of Functional A2a Adenosine Receptors in Human Neutrophil Membranes" <u>Br. J. Pharmacol.</u> 123:1723-1731						
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>				
<p><b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60390-1A/JPW/GJG/ML		Serial No. 10/718,280	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					Applicants: <b>Arlindo Castelhana et al.</b>			
					Filing Date <b>November 20, 2003</b>		Group <b>1624</b>	
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<b>FOREIGN PATENT DOCUMENTS</b>								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
	<b>108</b>	Von Lubitz D., et al., (1999) "Stimulation of Adenosine A3 Receptors in Cerebral Ischemia", <u>Ann. NY. Acad. Sci.</u> , 890: 93-106						
	<b>109</b>	Von Lubitz D., et al., (1999) "Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects", <u>European Journal of Pharmacology</u> , 367: 157-163						
	<b>110</b>	West, R.A. et al. (1961) "2-alkyl(aryl)-and 2,7-dimethyl-4-substituted aminopyrrolo[2,3-d]pyrimidines." <u>J. Org. Chem.</u> , 26:3809-3812						
	<b>111</b>	Yan, Luo et al. (2003) Expert Opinion on Emerging Drugs, vol. 8, no. 2 pp. 537-576						
	<b>112</b>	Yao Y., et al., (1997) "Adenosine A3 Receptor Agonists Protect HL-60 and U-937 Cells from Apoptosis Induced by A3 Antagonists", <u>Biochemical And Biophysical Research Communications</u> , 232: 317-322						
	<b>113</b>	Zhao Z., et al., (2000) "A role for the A3 Adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice", <u>Biochimica et Biophysica Acta</u> , 1500: 280-290						
	<b>114</b>	International Search Report issued in PCT International Application No. PCT/US99/12135, filed June 1, 1999						
	<b>115</b>	International Search Report issued in PCT International Application No. PCT/US00/32702, filed December 1, 2000						
	<b>116</b>	International Search Report issued in PCT International Application No. PCT/US2001/045280, filed November 30, 2001						
	<b>117</b>	International Search Report issued in PCT International Application No. PCT/US2002/38055, filed November 27, 2002						
	<b>118</b>	International Search Report issued in PCT International Application No. PCT/US2002/40890, filed December 20, 2002						
	<b>119</b>	International Search Report issued in PCT International Application No. PCT/US2002/41273, filed December 20, 2002						
	<b>120</b>	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US99/121358						
	<b>121</b>	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US00/32702						
	<b>122</b>	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2001/045280, filed November 30, 2001						
	<b>123</b>	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/38055, filed November 27, 2002						
	<b>124</b>	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/40890, filed December 20, 2002						
	<b>125</b>	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/41273, filed December 20, 2002						
	<b>126</b>	Supplemental European Search Report; for EP Application No. 02 80 5676; issued 2/7/2005						
	<b>127</b>	Partial European Search Report for EP Application No. 06 01 6543.8; completed 10/4/2006						
	<b>128</b>	Partial European Search Report; for EP Application No. 01 99 7029; completed 12/21/2004						
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								